A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With…The purpose of this study is to observe the safety of agalsidase alfa in Canadian patients with Fabry disease. Recruiting Principal Investigator Sandra SirrsArea Vancouver
Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) StudyCFDI STUDY with ENZYME REPLACEMENT THERAPY (ERT)Recruiting Principal Investigator Sandra SirrsBody Locations and Systems BrainArea VancouverAge 5-85
